loading

INVITRO INTERNATIONAL POSTS FISCAL YEAR 2007 SOLID SALES GAIN & RECORD PROFITS

Invitro International
Contact: W. Richard Ulmer
17751 Sky Park East, Suite G
(800) 2-INVITRO
Irvine, CA 92614
http://www.invitrointl.com
Irvine, CA December 10, 2007 – InVitro International (OTC, Pink Sheets, IVRO) today reported Fiscal Year 2007 sales of $741,714 and net profits of $69,273. These results compare to Fiscal Year 2006 sales of $608,920 and profits of $15,387, respectively. IVRO President/CEO, W. Richard Ulmer, said: “We are delighted to report our highest company sales since 1996, an advance of 21% over the prior year; an all time high in profits, as well as profits for the 4th year in our last five; a near doubling of sales in Latin Americal to more than 12% of company sales; approximately a two-thirds increase in European sales, sparked in great part by our wonderful investing Italian partner, ResPharma/INT.E.G.RA; and finally our U.S. sales advanced more than 18%. When we examine sales by technology, it was pleasing to see Irritection advance nearly 30% while Corrositex jumped 16% following its formal European acceptance published late in 2006. Similar Regulatory acceptance for Irritection is progressing per normal government review schedules.”

This press release may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: acceptance of the Company’s technology by customers or regulatory agencies, changes in market conditions and other competitive factors. Any such forward-looking statements are not guarantees of future performance.



CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS


Three months ended
September 30


Twelve months ended
September 30


2007


2006


2007


2006


Revenues


244,979


129,402


741,714


608,920


Costs and expenses


236,697


163,606


680,310


598,344


Income (loss) from operations


  8,282


(34,204)


61,404


10,576


Other income (loss)


1,938


2,070 


7,869


4,681


Net profit (loss)


10,220


(32,134)


69,273


15,257


Profit (loss) per common share


0.001


(0.002)


0.004


0.001


Weighted average common
shares outstanding


16,824,809


16,824,809


16,824,809


16,824,809

CONDENSED CONSOLIDATED BALANCE SHEET

 

 

 


September 30, 2007


September 30, 2006


Cash, cash equivalents and marketable securities


270,868


226,023


Other current assets


178,636


148,437


Total current assets


449,504


374,460


Noncurrent assets


53,369


35,183


Total assets


502,873


409,643


Current liabilities


62,245


38,288


Shareholders’ equity


440,628


371,355


Total liabilities and equity


502,873


409,643

Posted on Categories News

Leave a Reply

Your email address will not be published. Required fields are marked *